Vor Biopharma Inc. SEC filings VOR
Vor Biopharma Inc. has 462 filings in SEC EDGAR's recent list, going back to Jul 10, 2020. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 30, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Jul 7, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 6, 2026 | — |
| CORRESP | Letter to the SEC | May 4, 2026 | — |
| UPLOAD | Letter from the SEC | May 1, 2026 | — |
| EFFECT | Filing | Feb 4, 2026 | — |
| CORRESP | Letter to the SEC | Feb 2, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2026 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2025 | — |
| DEFR14A | Filing | Apr 30, 2025 | — |
| EFFECT | Filing | Mar 31, 2025 | — |
| CORRESP | Letter to the SEC | Mar 27, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2025 | — |
| EFFECT | Filing | Jan 29, 2025 | — |
| CORRESP | Letter to the SEC | Jan 27, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2025 | — |
| EFFECT | Filing | Dec 20, 2022 | — |
| CORRESP | Letter to the SEC | Dec 16, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2022 | — |
| EFFECT | Filing | Mar 18, 2022 | — |
| CORRESP | Letter to the SEC | Mar 16, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 16, 2022 | — |
| EFFECT | Filing | Feb 4, 2021 | — |
| SEC STAFF LETTER | Filing | Feb 4, 2021 | — |
| CERT | 8a cert | Feb 3, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| 8-A12B | Filing | Feb 1, 2021 | — |
| CORRESP | Letter to the SEC | Feb 1, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2021 | — |
| CORRESP | Letter to the SEC | Jan 21, 2021 | — |
| CORRESP | Letter to the SEC | Jan 15, 2021 | — |
| SEC STAFF LETTER | Filing | Jan 5, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 4, 2021 | — |
| DRSLTR | Filing | Dec 18, 2020 | — |
| DRS/A | Filing | Dec 18, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2020 | — |
| DRS | Filing | Nov 6, 2020 | — |
| D | Filing | Jul 10, 2020 | — |
Showing 37 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VOR (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1817229
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.